Integrative Analysis of CRC Liver Metastasis
- Conditions
- Metastasis
- Registration Number
- NCT02917707
- Lead Sponsor
- Da Fu
- Brief Summary
The investigators will perform integrative analysis of CRC liver metastasis
- Detailed Description
The investigators will analyzed proteomes of paired normal colorectal tissues and colorectal cancer (CRC) with or without liver metastasis, sequenced transcriptomes, performed whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal colorectal tissue, primary colorectal carcinoma, and its synchronous matched liver metastasis, as well as analyzed genomics of CRC characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1000
- Age ≤ 75 years with histologically proven CRC
- No severe major organ dysfunction
- WHO performance status of 0 or 1
- No prior cancer chemotherapy
- Age ≥ 76
- Severe major organ dysfunction
- World Health Organization (WHO) performance status of >1
- Prior cancer chemotherapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 5 years overall survival 5 years
- Secondary Outcome Measures
Name Time Method 5 years disease-free survival 5 years
Trial Locations
- Locations (2)
Ganzhou City People's Hospital
🇨🇳Ganzhou, Jiangxi, China
Shanghai Tenth People's Hospital
🇨🇳Shanghai, Shanghai, China
Ganzhou City People's Hospital🇨🇳Ganzhou, Jiangxi, ChinaXiaoming Zhong, MDSub Investigator